Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study.

Xiangrui MengJunsheng WangJin XiaTao WuZhiquan LuoYonggui HongPing LuYanzhen GuoYinghua JiMin ZhangLiuzhong YangPeng ChengWenchang LiangZhengzheng ShanYue ZhouMingyue WangTaiying LuMin SongHong ZongLijie SongWenkang WangLulu GuanYanke LiJianxiang XingSiyuan XingHan WuJingwen ChuXi LuoYao LuDao XinAijia LiBinghua JiangShenglei LiGuozhong JiangQingxia FanFeng ZhaoRongrong ZhengWenqing ZhuZhiguo HouYun JiaFeng Wang

Published in: European journal of cancer (Oxford, England : 1990) (2024)

This study showed that the confirmed ORR was modest and did not reach clinically meaningful improvement for patients with ESCC who were previously treated with ICIs, with a manageable safety profile.

Keyphrases

phase ii study
open label
locally advanced
clinical trial
radiation therapy
rectal cancer
study protocol
placebo controlled